Eli Lilly Diversifies Pipeline with $7 Billion Kelonia Therapeutics Acquisition

Eli Lilly (NYSE: LLY) is aggressively expanding its therapeutic reach, most notably through a $7 billion acquisition of Kelonia Therapeutics. This strategic move brings the KLN-1010 CAR-T gene therapy for cancer treatment into Lilly's pipeline, which is currently in phase 1 trials. The acquisition signals a concerted effort to diversify revenue streams beyond the company's dominant position in the burgeoning weight-loss drug market. By investing in oncology and gene therapy, Lilly aims to mitigate the risks associated with increasing competition in the metabolic health space. The company's commitment to innovation is reflected in its financial allocations; in 2025, Lilly spent 20.5% of its total revenue on research and development, with approximately one-quarter of its workforce dedicated to research. This investment strategy has yielded significant growth, with the company reporting a 43% year-over-year increase in revenue and a 51% jump in earnings per share (EPS) for the fourth quarter. From a valuation perspective, Lilly's forward price-to-earnings (P/E) ratio currently stands at 40. While this remains high, it is notably lower than the company's five-year average of 56, suggesting a more reasonable entry point relative to historical norms. The broader healthcare sector continues to provide a supportive macro backdrop. Total health spending increased by 7.2% from 2023 to 2024, a growth rate that exceeds the average annual increase seen throughout the 2010s, driven largely by an aging global population.